Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices 80159 

substance within this State . . . shall 

obtain a registration issued by the 

division in accordance with rules and 

regulations promulgated by it.’’). 

New Jersey statute defines 

‘‘practitioner’’ as a ‘‘physician.’’ N.J. 

Stat. Ann. § 24:21–2 (West, current with 

laws through L. 2020, c. 109 and J.R. No. 

2). It defines ‘‘physician’’ as ‘‘a 

physician authorized by law to practice 

medicine in this or any other state.’’ Id. 

Here, the weight of the evidence in 

the record is that Registrant’s license to 

practice medicine is currently 

suspended and that her CDS registration 

is inactive. In New Jersey, as already 

discussed, a ‘‘practitioner’’ must be a 

physician authorized by law to practice 

medicine. Id. As such, she is not a 

‘‘physician’’ or a ‘‘practitioner’’ as New 

Jersey statute defines those terms. Id. 

Thus, since Registrant lacks authority to 

practice medicine in New Jersey and 

does not have an active New Jersey CDS 

registration, she is not eligible to 

dispense controlled substances in that 

state. N.J. Stat. Ann. § 24:21–11(c). As 

such, based on the overwhelming record 

evidence and the law in New Jersey, I 

find that Registrant is not authorized to 

dispense controlled substances in New 

Jersey. 21 U.S.C. 824(a)(3). Accordingly, 

I will order that Registrant’s DEA 

registration be revoked. 

Order 

Pursuant to 28 CFR 0.100(b) and the 

authority vested in me by 21 U.S.C. 

824(a), I hereby revoke DEA Certificate 

of Registration No. FN5040136 issued to 

Anindita Nandi, M.D. This Order is 

effective January 11, 2021. 

Timothy J. Shea, 

Acting Administrator. 

[FR Doc. 2020–27235 Filed 12–10–20; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–748] 

Bulk Manufacturer of Controlled 

Substances Application: Sterling 

Pharma USA, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Sterling Pharma USA, LLC 

has applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before February 9, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before February 9, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on August 24, 2020, 

Sterling Pharma USA, LLC, 1001 

Sheldon Drive, Suite 101, Cary, North 

Carolina 27513–2079, applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Tetrahydrocannabinols .. 7370 I 

The company plans to manufacture in 

bulk drug code 7370 

(Tetrahydrocannabinols) exclusively 

from hemp extract, for distribution and 

sale to its customers. No other activities 

for this drug code is authorized for this 

registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2020–27240 Filed 12–10–20; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–752] 

Bulk Manufacturer of Controlled 

Substances Application: Johnson 

Matthey, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Johnson Matthey, Inc., has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before February 9, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before February 9, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on November 2, 2020, 

Johnson Matthey, Inc., 2003 Nolte Drive 

West Deptford, New Jersey 08066–1742, 

applied to be registered as an bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Marihuana ...................... 7360 I 

Tetrahydrocannabinols .. 7370 I 

Dihyromorphine ............. 9145 I 

Difenoxin ........................ 9168 I 

Amphetamine ................ 1100 II 

Methamphetamine ......... 1105 II 

Lisdexamfetamine ......... 1205 II 

Methylphenidate ............ 1724 II 

Nabilone ........................ 7379 II 

Norfentanyl .................... 8366 II 

Cocaine ......................... 9041 II 

Codeine ......................... 9050 II 

Dihydrocodeine .............. 9120 II 

Oxycodone .................... 9143 II 

Hydromorphone ............. 9150 II 

Diphenoxylate ................ 9170 II 

Ecgonine ........................ 9180 II 

Hydrocodone ................. 9193 II 

Levorphanol ................... 9220 II 

Meperidine ..................... 9230 II 

Methadone ..................... 9250 II 

Methadone intermediate 9254 II 

Morphine ........................ 9300 II 

Thebaine ........................ 9333 II 

Opium tincture ............... 9630 II 

Oxymorphone ................ 9652 II 

Noroxymorphone ........... 9668 II 

Alfentanil ........................ 9737 II 

Remifentanil ................... 9739 II 

Sufentanil ....................... 9740 II 

Tapentadol ..................... 9780 II 

Fentanyl ......................... 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. In reference to drug codes 

7360 (Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2020–27241 Filed 12–10–20; 8:45 am] 

BILLING CODE 4410–09–P 


jbell on DSKJLSW7X2PROD with NOTICES